4 Steps for Conducting an Early Feasibility Study in Costa Rica

Introduction

In the fast-evolving field of medical technology, Early Feasibility Studies (EFS) are crucial for success, especially in a region like Costa Rica that fosters innovation. By conducting an EFS, companies can assess the safety and functionality of their devices while expediting their path to market, capitalizing on significant cost savings and faster patient recruitment.

However, organizations often find themselves grappling with intricate regulatory landscapes that can stall progress. Organizations must strategically leverage Costa Rica’s advantages to navigate these hurdles and ensure successful early feasibility studies.

Understand Early Feasibility Studies and Their Importance

In the fast-evolving world of medical technology, Early Feasibility Studies (EFS) are essential for ensuring the safety and effectiveness of new devices. EFS serve as crucial preliminary investigations aimed at assessing the safety and functionality of medical devices or treatments during their early development stages. In Costa Rica, where the framework supports expedited approvals, conducting an EFS can significantly enhance the speed to market for innovative medical technologies. The primary objectives of an EFS include:

• Assessing Initial Safety: Identifying potential risks associated with the device or treatment to ensure patient safety.
• Evaluating Functionality: Testing whether the device operates as intended within a small cohort of subjects, typically involving 10 or fewer participants.
• Gathering Compliance Insights: Collecting data that can facilitate future submissions to authorities such as INVIMA, thereby streamlining the approval process.

Executing an EFS helps sponsors make informed decisions about their products, saving both time and resources in the long run. The FDA’s recent guidance on Investigational Device Exemptions (IDEs) for early feasibility evaluations emphasizes the significance of these investigations, especially when clinical experience is required due to inadequate non-clinical testing. This approach not only supports device innovation but also aligns with the strategic advantages offered by Latin America, including faster patient recruitment and reduced costs. As the landscape for early feasibility studies changes in 2026, understanding these dynamics will empower startups to navigate the complexities of clinical research and drive innovation forward.

Identify Regulatory Requirements for EFS in Costa Rica

Navigating the compliance landscape for an early feasibility study in Costa Rica presents unique challenges that require careful attention to regulatory details. To ensure a successful study, it’s crucial to follow the compliance framework established by the Ministry of Health and INVIMA. Here are the critical regulatory requirements you need to consider:

1. Device Classification: Start by determining the classification of your device using the Ministry of Health’s classification rules. This step is vital for establishing the appropriate regulatory pathway.
2. Protocol Submission: Develop a comprehensive protocol that outlines your objectives, methodology, and statistical analysis plans. This document must be submitted to INVIMA for approval, ensuring it meets all necessary criteria.
3. Ethics Committee Approval: Secure authorization from an acknowledged ethics committee (Comité de Ética) to ensure that your project complies with ethical norms and safeguards participant rights.
4. Informed Consent Forms: Create clear and compliant informed consent forms that inform participants about the purpose, procedures, risks, and benefits of the trial, in accordance with local regulations.
5. Regulatory Fees: Don’t forget to pay any applicable fees associated with the submission process to INVIMA, which are necessary for the review of your application.
6. Approval Timeline: Expect an approval timeline of roughly 30-60 days from INVIMA, depending on the complexity of your project and the completeness of the submitted documentation.

If you follow these steps, you’ll find that the approval process for your early feasibility study in Costa Rica can be much smoother, helping you launch without unnecessary delays. Moreover, conducting an early feasibility study in Costa Rica can save you 30-50% in costs compared to evaluations in the US or EU, making it a smart choice for MedTech, Biopharma, and Radiopharma firms. Utilizing insights from bioaccess®’s Global Trial Accelerators™ can further deepen your understanding of compliance updates and market access strategies, ensuring successful execution of your research.

Plan and Execute the Early Feasibility Study

Executing an early feasibility study Costa Rica presents unique challenges and opportunities that demand strategic planning and local expertise. Here are several critical steps that ensure compliance with local regulations and optimize participant engagement, leveraging the unique advantages of the region:

1. Site Selection: Choose clinical sites with proven experience in conducting EFS and access to the target patient population. It is essential that these sites comply with ICH-GCP standards and are familiar with local regulatory requirements set by INVIMA. This guarantees that the research adheres to both ethical and scientific standards. With bioaccess®, you can streamline site selection and tap into pre-negotiated contracts that save you up to $25K per patient.
2. Participant Recruitment: Have you considered how a targeted recruitment strategy can enhance your patient demographics? Develop a strategy that focuses on the right patient groups. Leverage local networks, patient registries, and community outreach to boost recruitment efforts. Engaging healthcare providers and utilizing digital platforms can significantly improve visibility and trust among potential participants. With bioaccess®, sponsors can benefit from a streamlined recruitment process that capitalizes on the region’s rapid enrollment capabilities, achieving 50% faster enrollment compared to other regions.
3. Training Research Personnel: Ensure that all staff involved in the trial are thoroughly trained on the protocol, ethical considerations, and informed consent processes. This training should also address methods for collecting information to uphold the integrity of the research. Bioaccess® provides comprehensive training resources to ensure compliance with local regulations and best practices.
4. Conducting the Study: Implement the study according to the approved protocol, closely monitoring adherence to ensure systematic collection of findings. Regular check-ins with site staff can help address any issues swiftly and maintain compliance with oversight expectations. With bioaccess®, sponsors can expect accelerated timelines, with ethics approvals in as little as 4-8 weeks, significantly faster than the 6+ months typical in the US/EU.
5. Information Management: Establish a robust information management plan that guarantees integrity and compliance with legal requirements. This encompasses performing routine audits and quality assessments to ensure that all information gathered meets the essential criteria for compliance submissions. Bioaccess® aids this process by offering tools and expertise to uphold high quality standards.
6. Reporting Results: After the research concludes, compile the outcomes into a comprehensive report suitable for submission to INVIMA and for further compliance submissions. This report should clearly outline the findings and their implications for future development.

By embracing these steps and the advantages of bioaccess®, sponsors can not only navigate the complexities of EFS but also position themselves for success in future clinical endeavors.

Troubleshoot Common Challenges in EFS Execution

Navigating the complexities of conducting an early feasibility study in Costa Rica requires a strategic approach to overcome common challenges. Leveraging insights from bioaccess®’s Global Trial Accelerators™ – which provide essential clinical trial insights and market access strategies – can significantly enhance your approach. Here are some common issues and strategies to troubleshoot them:

1. Recruitment Delays: Many sponsors face the daunting reality that a staggering 80-85% of clinical trials struggle with recruitment, leading to potential project delays. Have you considered revising your recruitment strategy? Engaging local patient advocacy groups can enhance awareness and trust. Utilizing social media can also broaden your reach, costing approximately $20 per qualified lead. Bioaccess® offers insights into local patient demographics and preferences, helping to tailor your recruitment efforts more effectively.
2. Protocol Deviations: Protocol adherence is critical, and deviations can lead to significant delays. Ensure that all personnel involved in the research are thoroughly trained on the protocol’s importance. Regular training sessions and reminders can help mitigate deviations, as studies show that 57% of protocols undergo at least one amendment, leading to time and financial losses. Bioaccess® can assist in developing training materials that emphasize compliance with ICH-GCP standards, ensuring that your team is well-prepared.
3. Integrity Issues: Implement a robust management system that includes regular audits and checks. Precise and timely entry of information is crucial, as manual entry of records is among the most time-consuming elements of trial management. Employing AI-driven analytics can simplify this process and lessen the need for retrospective cleaning of information. Bioaccess® offers tools and resources that improve data integrity and support compliance with legal requirements.
4. Regulatory Compliance: Maintain open communication with INVIMA and the ethics committee throughout the study. Address any compliance concerns promptly to avoid delays, as the process for gaining approval can take 6-12 months. Familiarize yourself with ICH-GCP standards and ensure that your data is FDA-bridgeable for IDE, 510(k), De Novo, PMA, and HDE submissions. Bioaccess® provides timely updates on regulatory changes and market access strategies, ensuring that you remain compliant and informed.
5. Participant Retention: Enhancing retention is crucial, especially considering that dropout rates in clinical trials average around 30%. Maintain regular communication with participants, offering updates on the project’s progress. Consider offering incentives for continued participation, which can significantly improve retention rates. Bioaccess® can help design retention strategies that resonate with local participants, increasing their commitment to the study.

By leveraging bioaccess®’s expertise, sponsors can not only navigate these hurdles but also position themselves for success in the competitive landscape of clinical research.

Conclusion

For MedTech and Biopharma companies, conducting an early feasibility study (EFS) in Costa Rica is not just beneficial; it’s essential for ensuring the safety and effectiveness of innovations. Understanding the regulatory landscape and leveraging the region’s unique advantages empowers sponsors to enhance their chances of successful product development and market entry.

Key insights from this guide emphasize the importance of thorough preparation, including:

1. Identifying regulatory requirements
2. Planning site selection
3. Executing the study with precision

Every step – from device classification to participant recruitment – must be executed with precision to ensure compliance with INVIMA and ethical standards, paving the way for a streamlined approval process. Moreover, addressing common challenges such as recruitment delays and protocol deviations with proactive strategies can further bolster the likelihood of a successful EFS.

As the landscape for early feasibility studies evolves, leveraging the strategic benefits of conducting trials in Costa Rica is crucial for achieving substantial time and cost savings. Companies are encouraged to embrace these insights and best practices, utilizing resources like bioaccess® to navigate complexities and optimize their clinical research efforts. Embracing these insights not only accelerates product development but also positions companies at the forefront of medical technology advancements in a rapidly evolving landscape.

Frequently Asked Questions

What are Early Feasibility Studies (EFS) in the context of medical technology?

Early Feasibility Studies (EFS) are preliminary investigations designed to assess the safety and functionality of new medical devices or treatments during their early development stages.

Why are Early Feasibility Studies important?

EFS are crucial for ensuring patient safety, evaluating device functionality, and gathering compliance insights to facilitate future submissions to regulatory authorities, thereby streamlining the approval process.

What are the primary objectives of an Early Feasibility Study?

The primary objectives of an EFS include assessing initial safety, evaluating functionality with a small cohort of participants (typically 10 or fewer), and gathering data to support future regulatory submissions.

How do Early Feasibility Studies impact the speed to market for medical technologies in Costa Rica?

The regulatory framework in Costa Rica supports expedited approvals, allowing EFS to significantly enhance the speed to market for innovative medical technologies.

What role does the FDA play in Early Feasibility Studies?

The FDA provides guidance on Investigational Device Exemptions (IDEs) for early feasibility evaluations, emphasizing the importance of these studies, especially when clinical experience is needed due to inadequate non-clinical testing.

What are the advantages of conducting Early Feasibility Studies in Latin America?

Latin America offers strategic advantages for EFS, including faster patient recruitment, reduced costs, and streamlined regulatory pathways, making it an attractive region for early-stage clinical trials.

How can understanding the dynamics of Early Feasibility Studies empower startups in clinical research?

By understanding the complexities and regulatory requirements associated with EFS, startups can make informed decisions, navigate clinical research effectively, and drive innovation in medical technology.

What regulatory authorities are involved in the approval process for Early Feasibility Studies?

Relevant regulatory authorities include INVIMA in Colombia, ANVISA in Brazil, and COFEPRIS in Mexico, which oversee the approval and compliance requirements for medical devices and treatments in their respective countries.

List of Sources

1. Understand Early Feasibility Studies and Their Importance
   • Early Feasibility Studies (EFS) Program (https://fda.gov/medical-devices/investigational-device-exemption-ide/early-feasibility-studies-efs-program)
   • Is the FDA Early Feasibility Studies Program right for you? (https://starfishmedical.com/resource/fda-early-feasibility-studies-program)
   • How does an Early Feasibility Study differ from a Pivotal Study? | MED Institute (https://medinstitute.com/blog/how-does-an-early-feasibility-study-differ-from-a-pivotal-study)
2. Identify Regulatory Requirements for EFS in Costa Rica
   • Early Feasibility Studies (EFS) for Medical Devices | bioaccess (https://bioaccessla.com/early-feasibility-studies)
   • Ultimate Guide for Regulatory Affairs in Costa Rica (https://veraqueconsulting.com/cr/guides/ultimate-guide-for-regulatory-affairs-in-costa-rica)
   • Costa Rica Regulatory Approval Process for Medical and IVD Devices (https://emergobyul.com/resources/costa-rica-regulatory-approval-process-medical-and-ivd-devices)
3. Plan and Execute the Early Feasibility Study
   • Enrollment Performance: Weighing the “Facts” | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/enrollment-performance-weighing-facts)
   • Enrollment and Retention: A Strategic Imperative for Clinical Trial Success – ConfidenceResearch (https://confidenceresearch.com/enrollment-and-retention-a-strategic-imperative-for-clinical-trial-success)
   • totaldiversity.com (https://totaldiversity.com/clinical-study-recruitment)
4. Troubleshoot Common Challenges in EFS Execution
   • 2025 Trends In Patient Recruitment: From Disruption To Precision (https://clinicalleader.com/doc/trends-in-patient-recruitment-from-disruption-to-precision-0001)
   • Plot Twist: 80% of Clinical Trials DO NOT Miss Enrollment Timelines Because of Poor Recruitment (https://proofpilot.com/blog/plot-twist-80-of-clinical-trials-do-not-miss-enrollment-timelines-because-of-poor-recruitment)
   • Why Time Is The Most Expensive Resource In Clinical Trials—And How To Make Every Second Count (https://blog.leapcure.com/why-time-is-the-most-expensive-resource-in-clinical-trials-and-how-to-make-every-second-count)
   • 140+ Clinical Trial Recruitment Statistics (2026, Verified) (https://gitnux.org/clinical-trial-recruitment-statistics)